Equity-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Schedule of stock option activity

The following table summarizes stock option activity for the nine months ended September 30, 2020:

	2019	2007	Lumara Health	Inducement
	Plan	Plan	2013 Plan	Grants	Total
Outstanding at January 1, 2020	472,412	2,585,466	131,775	696,164	3,885,817
Granted	420,912	—	—	1,000,000	1,420,912
Exercised	(18,487)	—	(1,450)	—	(19,937)
Expired or terminated	(149,863)	(672,295)	(43,250)	(188,098)	(1,053,506)
Outstanding at September 30, 2020	724,974	1,913,171	87,075	1,508,066	4,233,286

Schedule of restricted stock activity

The following table summarizes RSU activity for the nine months ended September 30, 2020:

	2019	2007	Lumara Health	Inducement
	Plan	Plan	2013 Plan	Grants	Total
Outstanding at January 1, 2020	128,742	1,407,305	2,167	41,223	1,579,437
Granted	825,131	—	—	—	825,131
Vested	(78,689)	(460,185)	(899)	(10,862)	(550,635)
Expired or terminated	(209,697)	(591,972)	(534)	(17,169)	(819,372)
Outstanding at September 30, 2020	665,487	355,148	734	13,192	1,034,561

Schedule of equity-based compensation expense

Equity-based compensation expense for the three and nine months ended September 30, 2020 and 2019 consisted of the following (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Cost of product sales	$	131	$	225	$	438	$	626
Research and development	237		691		260		2,051
Selling, general and administrative	1,854		4,058		7,403		11,039
Total equity-based compensation expense	2,222		4,974		8,101		13,716
Income tax effect	—		—		—		—
After-tax effect of equity-based compensation expense	$	2,222	$	4,974	$	8,101	$	13,716